The Role of a New Prosthodontics Device in Hard and Soft Tissue Changes After Subcrestal Implant Placement

NCT ID: NCT06182670

Last Updated: 2023-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-06

Study Completion Date

2023-06-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present randomized controlled trial aims to assess the influence of a new prosthodontics device (Gingival Former Abutment -GFA) on peri-implant bone loss and soft tissue changes and health after subcrestal oral implant placement.

The participants will be divided in two groups and receive either crestal implant placement and traditional healing abutment or subcrestal implant placement and GFA.

Clinical and radiographic examination will be performed at implant placement surgery, prosthetic load, 6 and 12 months follow-up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

According to current literature, physiological bone loss around oral implants is expected after placement and load (1 mm during the first year and 0.2 mm each subsequent year). Different implant designs and surgical protocols have been tested to minimize bone resorption, and subcrestal implant placement partially seems to overcome this issue. However, if this procedure increases the length of the transmucosal tunnel, increasing the risk of peri-implant soft tissue infection.

The GFA was created to limit both the loss of peri-implant crestal bone and the extension of the transmucosal tunnel. The GFA follows the "one abutment one time" concept, which is believed to limit disturbances of the peri-implant hard and soft tissues healing due to the removal of the traditional healing abutments during prosthetic load procedures. Our objective is to validate or deny this claim.

The study is a monocentric, pragmatic, single-blinded, randomized clinical trial (RCT) of parallel design. The trial will have a one-year duration, with data collection at the surgical phase, at implant load and 6 and 12 months after load. The primary outcome will be radiographical MBL (marginal bone level) changes around the implant. Secondary outcomes will be the assessment of the peri-implant soft tissues.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Edentulous Alveolar Ridge

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Oral Implants Abutment Subcrestal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Monocentric, single blinded, randomized clinical trial, parallel design.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
Single

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subcrestal implant and gingival former abutment (GFA)

The subjects receive a subcrestal implant and a prosthodontic device (GFA) immediately during the surgery. The GFA will not be removed upon prosthetic load. It will be an integral part of the prosthetic finalization.

Group Type EXPERIMENTAL

Gingival Former Abutment

Intervention Type DEVICE

GFA is positioned on the sub-crestal implant during the surgery and it is no longer removed. This follows the "one abutment one time" concept and should prevent bone loss and transmucosal tunnel.

Subcrestal Implant

Intervention Type PROCEDURE

Placement of the endosseous sub-crestal dental implant through dedicated drills with 35 Newton insertion torque. It is positioned 2 mm under the crestal bone.

Prosthetic Crown

Intervention Type DEVICE

A zirconia prosthetic crown finalizes the implant rehabilitation.

Crestal implant and traditional abutment

The subjects receive a crestal implant and healing abutment. The healing abutment will be replaced by a definitive abutment to the prosthetic load.

Group Type ACTIVE_COMPARATOR

Healing Abutment

Intervention Type DEVICE

A healing abutment is positioned on crestal implant during surgery. It is removed at prosthetic finalization.

Prosthetic Crown

Intervention Type DEVICE

A zirconia prosthetic crown finalizes the implant rehabilitation.

Crestal Implant

Intervention Type PROCEDURE

Placement of the endosseous crestal implant through dedicated drills with 35 Newton insertion torque at level of the alveolar bone.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gingival Former Abutment

GFA is positioned on the sub-crestal implant during the surgery and it is no longer removed. This follows the "one abutment one time" concept and should prevent bone loss and transmucosal tunnel.

Intervention Type DEVICE

Subcrestal Implant

Placement of the endosseous sub-crestal dental implant through dedicated drills with 35 Newton insertion torque. It is positioned 2 mm under the crestal bone.

Intervention Type PROCEDURE

Healing Abutment

A healing abutment is positioned on crestal implant during surgery. It is removed at prosthetic finalization.

Intervention Type DEVICE

Prosthetic Crown

A zirconia prosthetic crown finalizes the implant rehabilitation.

Intervention Type DEVICE

Crestal Implant

Placement of the endosseous crestal implant through dedicated drills with 35 Newton insertion torque at level of the alveolar bone.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to comprehend and sign informed consent.
* Male and female subjects, aged 18-75 years, inclusive.
* Good general health (free of systemic diseases such as diabetes, HIV infection or genetic disorder, ongoing malignant disease of any type that could influence the outcome of the treatment and might interfere with the evaluation of the study objectives).
* Good oral health (no decay, periapical or periodontal lesions, PI and BOP \<25%).
* Patient with posterior single missing tooth:

* for at least 5 months,
* mandibular or maxillary,
* intercalated (distance between teeth more than 7.5 mm),
* at least 11 mm of height residual bone (from bone crest to maxillary sinus or inferior alveolar nerve),
* at least 5 mm of bone width (buccal - palatal/lingual).
* Availability for the 12-month duration of the study.

Exclusion Criteria

* Not willing to follow the agreed protocol.
* Presence of orthodontic appliances.
* Smokers more than 10 cigarettes per day.
* Chronic obstructive pulmonary disease and asthma.
* Tumors or significant pathology of the soft or hard tissues of the oral cavity.
* Current radiotherapy or chemotherapy.
* Pregnant or lactating women.
* Parafunctions like bruxism.
* Previous interventions to increase bone thickness in the implant area.
* Current or past assumption of medications that may influence surgical therapy and/or interfere with healing following surgical treatment.
* Systemic diseases that constitute a contraindication to surgical therapy and/or interfere with healing following surgical treatment.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Magda Mensi

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Magda Mensi

Role: PRINCIPAL_INVESTIGATOR

ASST Spedali Civili di Brescia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Magda Mensi

Brescia, Lombardy, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NABUT NP 4078

Identifier Type: -

Identifier Source: org_study_id